Skip to content

LUng voluMe reductIoN by DuAl ENergy CT Evaluation (LUMINANCE) Study

LUng voluMe reductIoN by DuAl ENergy CT Evaluation (LUMINANCE) Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05816239
Enrollment
13
Registered
2023-04-18
Start date
2023-02-24
Completion date
2025-05-24
Last updated
2025-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Perfusion

Brief summary

The purpose of this research study is to see if a special CT scan (dual-energy CT) provides useful information in patients undergoing bronchsoscopic lung volume reduction (valve placement for emphysema). The investigators will enroll up to 30 participants in this study from University Hospitals Cleveland Medical Center. All of the participants from this study will undergo their valve procedure at University Hospitals Cleveland Medical Center.

Interventions

Patient will receive Dual Energy CT

Sponsors

Sameer Avasarala
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (≥ 18 years of age at the time of written informed consent) with emphysema who have been deemed appropriate candidates for bronchoscopic lung volume reduction

Exclusion criteria

* Patients unable to provide consent * Patients who are pregnant or nursing * Women of child-bearing age will undergo pregnancy tests based on University Hospital (UH) standard bronchoscopy pre-procedural testing * Patients unable to undergo a DECT chest (contraindications to a CT chest with intravenous contrast such as a reported or documented allergy to intravenous (IV) contrast or impaired renal function, defined as the following: * Glomerular filtration rate (GFR) \<90 ml/min/1.73 m2 at the time of initial evaluation if patient age is ≤ 59 years * GFR \<85 ml/min/1.73 m2 if patient age is 60-69 years * GFR \<75 ml/min/1.73 m2 if patient age is ≥70 years

Design outcomes

Primary

MeasureTime frame
Change in lung perfusion as measured by duel-energy computed tomographyBaseline, 8 weeks
Change in walk distance as measured by six-minute walk testBaseline, 8 weeks
Change in FEV1 as measured by pulmonary function testBaseline, 8 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026